As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
BUSINESS
Shionogi’s COVID-19 Pill Improves Respiratory and Feverish Symptoms
Shionogi’s oral COVID-19 treatment S-217622 improved respiratory and feverish symptoms associated with the disease as compared to placebo, according to new data released by the company. The Osaka drug maker said that S-217622 showed no statistically significant difference versus placebo…
To read the full story
Related Article
- Japan Govt to Purchase Another 1 Million Courses of Xocova
December 14, 2022
- Japan Should Hone Emergency Approval Scheme Based on Xocova Example
November 28, 2022
- Shionogi Chief Defends Xocova Data, Eager to Prove Benefits in Clinical Settings
November 25, 2022
- Japan Grants 1st Emergency Approval to Shionogi COVID Pill Xocova
November 24, 2022
- Shionogi Launches 4th-Dose COVID Jab Trial for Ages 60-Plus
July 27, 2022
- Japan Again Takes Pass on Emergency Approval for Shionogi’s COVID Pill as Panels Nix Presumed Efficacy
July 21, 2022
- Shionogi Begins COVID-19 Vaccine Trial in Children Aged 5-11
July 20, 2022
- Japan Shelves Decision on Shionogi’s COVID Pill with Experts at Odds, Another Session Likely Next Month
June 23, 2022
- Shionogi’s COVID Pill Up for PAFSC Review for 1st Emergency Approval
June 16, 2022
- Shionogi’s COVID-19 Vaccine Enters PII/III with Japanese Adolescents
May 17, 2022
- Large-Scale Japan Trial for Shionogi Jab Confirms No Major Safety Concerns, Increase in Antibody Titers
April 25, 2022
- Japan Inks Supply Deal for Shionogi’s COVID Pill for 1 Million People
March 25, 2022
- FDA Clears Shionogi’s COVID-19 Pill for Global PIII Study
March 17, 2022
- Shionogi’s COVID-19 Jab Non-Inferior to Pfizer Shot in Japan Booster Trial
March 7, 2022
- Japan to Expedite Review for Shionogi’s COVID-19 Pill: PM
March 1, 2022
- Shionogi Files COVID-19 Pill in Japan, Seeks Conditional Approval
February 25, 2022
- Lawmakers Mixed on Use of Conditional Approval for Shionogi’s COVID-19 Pill
February 16, 2022
- MHLW to Consider Conditional Approval for Shionogi COVID Pill: Minister
February 9, 2022
- Shionogi Looks to File COVID Pill in Japan as Early as Next Week
February 8, 2022
- Japan Mulls Early Conditional Approval for Shionogi’s COVID Pill
February 8, 2022
- Japan Won’t Give 3rd-Shot Approval for Shionogi’s Jab with Booster Trial Alone
February 1, 2022
- Shionogi’s COVID-19 Vaccine Enters Japan PIII, AstraZeneca Jab as Control
January 18, 2022
- Shionogi’s COVID-19 Pill Submission Delaying into 2022 as Recruitment Hits Snag
January 6, 2022
- Shionogi Launches Global PIII for COVID-19 Vaccine
December 28, 2021
- Shionogi’s COVID-19 Vaccine Safe and Tolerable, Increases Antibody Titers: Japan PI/II
December 8, 2021
- Shionogi Kicks Off COVID-19 Booster Trial in Japan
December 6, 2021
- Shionogi Wants to Pick Global Partner for Oral COVID-19 Drug by Year-End: President
November 2, 2021
- Shionogi Launches Japan PII/III for COVID-19 Vaccine
October 22, 2021
- Shionogi Chief Expresses Eagerness for COVID-19 Drug Rollout, PII/III to Wrap Up by Year-End
September 30, 2021
- Shionogi Kicks Off Japan PII/III Trial for Oral COVID-19 Drug
September 29, 2021
- Secure Domestic Supply of Oral COVID-19 Med: Komeito to Govt
September 27, 2021
- Shionogi to Begin PII/III Study for Oral COVID-19 Drug on Sept. 27: President
September 24, 2021
- Shionogi Gets New Oral COVID-19 Drug into Clinic in Less than 1 Year, Now Gearing Up for PII/III
September 24, 2021
- All 60 Subjects Given 1st Dose of Shionogi COVID-19 Jabs in Japan PI/PII
August 25, 2021
- Shionogi Kicks Off Japan PI/PII Study of COVID-19 Vaccine Candidate
December 17, 2020
BUSINESS
- Despite Spike in Flu Cases, Vaccine Shipments Down in FY2024: Wholesalers
January 28, 2025
- Nippon Shinyaku Bags US License Option for AB2 Bio’s Tadekinig Alfa
January 28, 2025
- Leqembi’s Monthly IV Maintenance Dosing Approved in US
January 28, 2025
- Astellas Slashes Full-Year Profit Forecasts on Impairment Loss of Izervay and More
January 27, 2025
- Rakuten Medical Launches Global PIII Trial of Photoimmunotherapy/Keytruda Combo
January 27, 2025
A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…